Nanjing Medlander Medical Technology Co. Ltd. A (688273) — Capital Reinvestment Ratio
Nanjing Medlander Medical Technology Co. Ltd. A (688273) has a Capital Reinvestment Ratio of 1.06x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥122.51 Million) in capital expenditures (CN¥129.71 Million). Check 688273 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Medlander Medical Technology Co. Ltd. A Capital Reinvestment Ratio (2020–2024)
This chart tracks Nanjing Medlander Medical Technology Co. Ltd. A's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see how efficiently does Nanjing Medlander Medical Technology Co. generate cash.
Annual Capital Reinvestment Ratio for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)
Year-by-year Capital Reinvestment Ratio for Nanjing Medlander Medical Technology Co. Ltd. A from 2020 to 2024. See free cash flow generation of Nanjing Medlander Medical Technology Co. to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.06x | CN¥122.51 Million | CN¥129.71 Million | ▲ +92.9% |
| 2023 | 0.55x | CN¥136.91 Million | CN¥75.15 Million | ▲ +28.1% |
| 2022 | 0.43x | CN¥126.67 Million | CN¥54.26 Million | ▲ +336.4% |
| 2021 | 0.10x | CN¥148.60 Million | CN¥14.58 Million | ▼ -50.3% |
| 2020 | 0.20x | CN¥131.10 Million | CN¥25.91 Million | — |